Trials / Active Not Recruiting
Active Not RecruitingNCT05791201
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-264 | Allogeneic human stem cell-derived islets. |
Timeline
- Start date
- 2023-05-16
- Primary completion
- 2026-05-29
- Completion
- 2026-05-29
- First posted
- 2023-03-30
- Last updated
- 2025-08-11
Locations
16 sites across 7 countries: United States, Canada, Germany, Italy, Netherlands, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05791201. Inclusion in this directory is not an endorsement.